News Releases

San Diego, March 13, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, March 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, February 7, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, January 19, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, January 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, November 30, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, November 21, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, November 14, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, November 10, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...

San Diego, November 2, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is scheduled to...

San Diego, September 19, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with the...

Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of...

First orphan drug designation granted for Nana-val by the European Commission; fifth globally SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to...

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) expanding into Stage 2 is anticipated...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston, M.D.,...

Trial has advanced to the second dose escalation cohort with no dose-limiting toxicities observed to-date SAN DIEGO, June 2, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the Jefferies...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one...

Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage...

Virtual event to take place on Wednesday, April 27, 2022, at 11:00 AM EDT SAN DIEGO, April 20, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21st Annual...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors...

Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma featured in an oral...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to participate in a fireside...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, the company's President and Chief Executive...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the first patient has been dosed in the multinational Phase...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C....

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the presentation of new preclinical data on vecabrutinib, a...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that final data from its Phase 1b/2 trial of Nana-val in...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted its...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the third quarter of 2021 and provided an...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced that the Company has entered into a loan and...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced the acceptance of two abstracts for oral...

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of a multinational Phase 1b/2 trial in patients with...

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and be available for virtual...

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointments of Flavia Borellini, Ph.D., and Jane F. Barlow,...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the second quarter of 2021 and provided...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has cleared...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been added as a member of the small-cap Russell 2000®...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of NAVAL-1 (Nanatinostat in Combination with...

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies...

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and...

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced financial results for the first quarter of...

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) announced today XOMA has purchased the potential future milestones and royalties associated with existing licenses...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life...

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc....

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has...

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci...

PR Newswire, San Diego, December 7, 2020 - Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent...

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., November 30, 2020 (GLOBE NEWSWIRE) - Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology...

PR Newswire, San Diego, October 8, 2020 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston,...

Viracta Therapeutics, Inc. ("Viracta" or the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as...

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of...

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish, MD, PhD, has joined Viracta as a...

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors....

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance...

PR Newswire, San Diego, June 24, 2020 - Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination...

SAN DIEGO, May 28, 2020 - Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader...

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive...

PR Newswire, San Diego, March 25, 2020 – Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa...

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, M.D., the Company's President and CEO, will...

PR Newswire, San Diego, February 4, 2020 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that Dan...

PR Newswire, San Diego, December 8, 2019 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead...

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will...

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast...

PR Newswire, San Diego, November 6, 2019 – Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that its lead...

PR Newswire, San Diego, October 28, 2019 – Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced the closing of a Series D Preferred...

SAN DIEGO, Oct. 14, 2019 /PRNewswire/ – Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, MD, President and...

PR Newswire, San Diego, August 1, 2019 – Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice...

PR Newswire, San Diego, June 3, 2019 – Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial...

PR Newswire, San Diego, May 15, 2019 – – Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical...

PR Newswire, San Diego, April 16, 2019 – Viracta Therapeutics, Inc. announced today that the U. S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2...

San Diego, CA and Shenzhen, China, December 4, 2018 - Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a...

San Diego, CA, September 25, 2018 - Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious...

San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has...

Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with

By Emily Cukier-Meisner, Senior Writer Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc.

San Diego and London; November 30, 2016 – Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. Viracta plans...